Gliclazide 21187-98-4
Gliclazide is an oral hypoglycemic and is classified as a sulfonylurea. It is marketed as Glyloc and Reclide in India. The modified-release formulation are also marketed now. Its classification has been ambiguous, as literature uses it as both a first-generation and second-generation sulfonylurea.
Form and Composition
Each tablet contains 80, 60, or 30 mg of gliclazide. Gliclazide is not marketed in the United States and Philippines. In the Philippines, it is marketed under the brandname of Glubitor-OD in 30 mg or 80 mg doses.
Indication
Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset or adult type. It is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate.
Mode of Action
Glimepiride {{Clarify
post-text=(cut and paste error?)
date=April 2010
| Systematic (IUPAC) name: | N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide |
|---|---|
| Gliclazide CAS number: | 21187-98-4 |
| ATC code: | A10BB09 |
| PubChem: | 3475 |
| DrugBank: | APRD00460 |
| Formula: | C15 H21 N3 O3 |
| Molecular mass: | 323.412 [[Gram g/mol |
| Gliclazide Assay/Purity: | Typically NLT 98% |
